No Data
Jianmin Pharmaceutical Group (600976.SH) plans to donate a batch of Pharmaceuticals valued at approximately 1 million yuan to areas in Tibet affected by the earthquake.
On January 13, Gelonghui reported that Jianmin Pharmaceutical Group (600976.SH) announced that on January 7, 2025, a magnitude 6.8 earthquake occurred in Dingri County, Shigatse City, Tibet. To support the emergency rescue work in the earthquake-affected areas of Tibet, the company or its subsidiaries plan to donate a batch of pharmaceuticals worth approximately 1 million yuan to the earthquake-affected areas through the China Population Welfare Foundation.
Jianmin Pharmaceutical Group (600976.SH): A subsidiary plans to invest 12.31 million yuan to renovate the pre-processing building.
On December 17, Gelonghui reported that Jianmin Pharmaceutical Group (600976.SH) announced that the Board of Directors approved its wholly-owned subsidiary Jianmin Pharmaceutical Group Yekai Thailand Co., Ltd. to invest 12.31 million yuan from its own funds to renovate the preprocessing building.
Jianmin Pharmaceutical Group (600976.SH): A controlled subsidiary plans to invest 5 million yuan to open a new traditional Chinese medicine clinic in the Optics Valley area.
Gelonghui, December 17th丨Jianmin Pharmaceutical Group (600976.SH) announced that the Board of Directors approved its holding subsidiary Jianmin Yekai Thai Medical Investment (Hubei) Co., Ltd. to invest 5 million yuan from its own funds to open a new traditional Chinese medicine clinic in the Optics Valley area.
Cautious Investors Not Rewarding Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) Performance Completely
jianmin pharmaceutical group (600976.SH): the company's new product entries and renewed listings in the national medical insurance catalog.
On November 28, Gelonghui reported that jianmin pharmaceutical group (600976.SH) announced that the National Healthcare Security Administration and the Ministry of Human Resources and Social Security released a notice regarding the publication of the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Pharmaceutical Catalogue (2024)." According to this notice, the company's product, Pediatric Zibei Xuanfei Syrup, has been included in the "National Basic Medical Insurance Catalogue (2024)" for the first time through negotiation, and Qirui Weishu Capsules will continue to be included in the "National Medical Insurance Catalogue (2024)" under the negotiation renewal period.
Is Jianmin Pharmaceutical GroupLtd (SHSE:600976) A Risky Investment?
Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Solid Profits Have Weak Fundamentals